DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

Dexcom, Inc. focuses on the design, development, and commercialization of CGM systems in the United States and internationally to support the management of diabetes and metabolic health by patients, ...

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

Dexcom Inc. (DXCM) reported its fourth-quarter 2025 earnings, surpassing analyst expectations with an EPS of $0.68 against a forecast of $0.65, a 4.62% surprise. Revenue reached $1.26 billion, ...

In December, Howard Marks published an investment memo titled, “Is it a bubble?” that expressed some of his skepticism and reservations about artificial intelligence and the stock-market boom it had ...

Howard Marks is much less skeptical about AI than he was just a few months ago. In December, Howard Marks published an investment memo titled, "Is it a bubble?" that expressed some of his skepticism ...